We are live on ! Find out more
CHNA

Loncar China BioPharma ETF
CHNA

Delisted

CHNA was delisted on the 20th of October, 2023.

Back to rankings

3 hedge funds and large institutions have $8.83K invested in Loncar China BioPharma ETF in 2023 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

40% less funds holding

Funds holding: 5 → 3 (-2)

98% less capital invested

Capital invested by funds: $574K → $8.83K (-$565K)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 2

Holders
3
Holders Change
-2
Holders Change %
-40%
% of All Funds
0.05%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
Jane Street
Jane Street
New York
-$560K
2
UBS Group
UBS Group
Switzerland
-$4.73K
Name Holding Trade Value Shares
Change 		Change in
Stake
BBPWM
1
Blue Bell Private Wealth Management
Pennsylvania
$5.49K – – –
Morgan Stanley
2
Morgan Stanley
New York
$3.35K – – –
Jane Street
3
Jane Street
New York
– -$560K -29,839 Closed
UBS Group
4
UBS Group
Switzerland
– -$4.73K -252 Closed

CHNA Hedge Fund Activity: Q1 2023 in Review

3 of the 6,276 institutional investors tracked by Wall St. Rank reported a position in Loncar China BioPharma ETF (CHNA) for Q1 2023, worth a combined $8.83K — down 98% from $574K a quarter earlier.

Sellers outnumbered buyers: 2 funds closed out of CHNA and 0 opened new positions — a net loss of 2 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was Jane Street, exiting entirely with an estimated $560K sold.

  • 3 institutional investors held Loncar China BioPharma ETF (CHNA) as of Q1 2023, down from 5 in Q4 2022.
  • Funds reported $8.83K of Loncar China BioPharma ETF stock for Q1 2023, down 98% quarter-over-quarter.
  • 0 funds opened new Loncar China BioPharma ETF positions in Q1 2023 and 2 closed out, a net change of -2 holders.
  • The largest Loncar China BioPharma ETF seller in Q1 2023 was Jane Street, an estimated $560K sold.

Based on aggregated 13F filings for Q1 2023.